annual total liabilities:
$48.90B-$2.87B(-5.54%)Summary
- As of today (August 16, 2025), TAK annual total liabilities is $48.90 billion, with the most recent change of -$2.87 billion (-5.54%) on March 1, 2025.
- During the last 3 years, TAK annual total liabilities has fallen by -$12.85 billion (-20.81%).
- TAK annual total liabilities is now -37.11% below its all-time high of $77.76 billion, reached on March 31, 2019.
Performance
TAK Total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly total liabilities:
$49.42B+$520.16M(+1.06%)Summary
- As of today (August 16, 2025), TAK quarterly total liabilities is $49.42 billion, with the most recent change of +$520.16 million (+1.06%) on June 1, 2025.
- Over the past year, TAK quarterly total liabilities has dropped by -$2.98 billion (-5.68%).
- TAK quarterly total liabilities is now -38.63% below its all-time high of $80.53 billion, reached on June 30, 2019.
Performance
TAK quarterly total liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Total liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
TAK Total liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -5.5% | -5.7% |
| 3 y3 years | -20.8% | -13.3% |
| 5 y5 years | -34.8% | -32.7% |
TAK Total liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -20.8% | at low | -13.5% | +1.1% |
| 5 y | 5-year | -34.8% | at low | -33.3% | +1.1% |
| alltime | all time | -37.1% | +1526.3% | -38.6% | +1010.5% |
TAK Total liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $49.42B(+1.1%) |
| Mar 2025 | $48.90B(-5.5%) | $48.90B(-0.0%) |
| Dec 2024 | - | $48.92B(-8.6%) |
| Sep 2024 | - | $53.49B(+2.1%) |
| Jun 2024 | - | $52.40B(+1.2%) |
| Mar 2024 | $51.77B(-9.4%) | $51.77B(-2.4%) |
| Dec 2023 | - | $53.06B(+1.5%) |
| Sep 2023 | - | $52.28B(-4.0%) |
| Jun 2023 | - | $54.46B(-4.7%) |
| Mar 2023 | $57.13B(-7.5%) | $57.13B(+2.9%) |
| Dec 2022 | - | $55.54B(+2.1%) |
| Sep 2022 | - | $54.41B(-4.6%) |
| Jun 2022 | - | $57.03B(-7.6%) |
| Mar 2022 | $61.75B(-11.8%) | $61.75B(-3.5%) |
| Dec 2021 | - | $63.97B(-1.4%) |
| Sep 2021 | - | $64.85B(-3.0%) |
| Jun 2021 | - | $66.84B(-4.5%) |
| Mar 2021 | $70.00B(-6.6%) | $70.00B(-5.5%) |
| Dec 2020 | - | $74.06B(+0.9%) |
| Sep 2020 | - | $73.42B(-0.0%) |
| Jun 2020 | - | $73.44B(-2.0%) |
| Mar 2020 | $74.97B(-3.6%) | $74.97B(-0.1%) |
| Dec 2019 | - | $75.04B(+1.2%) |
| Sep 2019 | - | $74.12B(-8.0%) |
| Jun 2019 | - | $80.53B(+3.6%) |
| Mar 2019 | $77.76B(+295.9%) | $77.76B(+129.1%) |
| Dec 2018 | - | $33.95B(+83.4%) |
| Sep 2018 | - | $18.51B(-2.0%) |
| Jun 2018 | - | $18.90B(-3.8%) |
| Mar 2018 | $19.64B(-8.7%) | $19.64B(-2.8%) |
| Dec 2017 | - | $20.21B(+0.2%) |
| Sep 2017 | - | $20.17B(-1.9%) |
| Jun 2017 | - | $20.55B(-4.9%) |
| Mar 2017 | $21.52B(+33.4%) | $21.60B(+20.1%) |
| Dec 2016 | - | $17.98B(-5.3%) |
| Sep 2016 | - | $18.99B(+0.0%) |
| Jun 2016 | - | $18.99B(+17.7%) |
| Mar 2016 | $16.13B(-7.4%) | $16.13B(-4.3%) |
| Dec 2015 | - | $16.85B(-0.6%) |
| Sep 2015 | - | $16.96B(-0.7%) |
| Jun 2015 | - | $17.07B(-2.0%) |
| Mar 2015 | $17.43B(-11.5%) | $17.43B(+0.4%) |
| Dec 2014 | - | $17.35B(-6.7%) |
| Sep 2014 | - | $18.60B(-5.0%) |
| Jun 2014 | - | $19.58B(+1.5%) |
| Mar 2014 | $19.70B(+8.0%) | $19.29B(+2.8%) |
| Dec 2013 | - | $18.77B(-3.4%) |
| Sep 2013 | - | $19.42B(+16.4%) |
| Jun 2013 | - | $16.68B(-9.5%) |
| Mar 2013 | $18.23B | $18.42B(-4.1%) |
| Dec 2012 | - | $19.21B(-1.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2012 | - | $19.42B(+2.1%) |
| Jun 2012 | - | $19.02B(+4.0%) |
| Mar 2012 | $18.29B(+133.3%) | $18.29B(-2.7%) |
| Dec 2011 | - | $18.80B(-0.4%) |
| Sep 2011 | - | $18.87B(+155.2%) |
| Jun 2011 | - | $7.39B(-5.7%) |
| Mar 2011 | $7.84B(+12.4%) | $7.84B(+8.2%) |
| Dec 2010 | - | $7.24B(+1.7%) |
| Sep 2010 | - | $7.12B(+5.2%) |
| Jun 2010 | - | $6.77B(-2.9%) |
| Mar 2010 | $6.98B(-0.9%) | $6.98B(+0.5%) |
| Dec 2009 | - | $6.95B(-4.5%) |
| Sep 2009 | - | $7.27B(+3.3%) |
| Jun 2009 | - | $7.04B(+0.0%) |
| Mar 2009 | $7.04B(+34.1%) | $7.04B(+0.4%) |
| Dec 2008 | - | $7.01B(-5.5%) |
| Sep 2008 | - | $7.42B(-2.8%) |
| Jun 2008 | - | $7.64B(+45.5%) |
| Mar 2008 | $5.25B(+4.5%) | - |
| Mar 2008 | - | $5.25B(+4.6%) |
| Dec 2007 | - | $5.02B(-0.7%) |
| Sep 2007 | - | $5.05B(+6.2%) |
| Jun 2007 | - | $4.76B(-5.2%) |
| Mar 2007 | $5.02B(-6.6%) | - |
| Mar 2007 | - | $5.02B(+1.2%) |
| Dec 2006 | - | $4.96B(+4.9%) |
| Sep 2006 | - | $4.73B(-6.2%) |
| Jun 2006 | - | $5.05B(-6.1%) |
| Mar 2006 | $5.37B(+15.1%) | - |
| Mar 2006 | - | $5.37B(+6.8%) |
| Dec 2005 | - | $5.03B(-0.1%) |
| Sep 2005 | - | $5.03B(+12.7%) |
| Jun 2005 | - | $4.47B(-1.8%) |
| Mar 2005 | $4.67B(-5.2%) | - |
| Mar 2005 | - | $4.55B(-4.5%) |
| Dec 2004 | - | $4.77B(+7.1%) |
| Sep 2004 | - | $4.45B(-1.1%) |
| Jun 2004 | - | $4.50B |
| Mar 2004 | $4.92B(+29.4%) | - |
| Mar 2003 | $3.80B(-0.3%) | - |
| Mar 2002 | $3.82B(-2.9%) | - |
| Mar 2001 | $3.93B(+4.2%) | - |
| Mar 2000 | $3.77B(+14.4%) | - |
| Mar 1999 | $3.30B(+9.6%) | - |
| Mar 1998 | $3.01B(-15.1%) | - |
| Mar 1997 | $3.54B(-7.6%) | - |
| Mar 1996 | $3.83B(-23.7%) | - |
| Mar 1995 | $5.02B(+23.4%) | - |
| Mar 1994 | $4.07B(+6.8%) | - |
| Mar 1993 | $3.81B(+20.4%) | - |
| Mar 1992 | $3.17B(+3.8%) | - |
| Mar 1991 | $3.05B | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual total liabilities?
- What is the all time high annual total liabilities for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual total liabilities year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly total liabilities?
- What is the all time high quarterly total liabilities for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly total liabilities year-on-year change?
What is Takeda Pharmaceutical Company Limited annual total liabilities?
The current annual total liabilities of TAK is $48.90B
What is the all time high annual total liabilities for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual total liabilities is $77.76B
What is Takeda Pharmaceutical Company Limited annual total liabilities year-on-year change?
Over the past year, TAK annual total liabilities has changed by -$2.87B (-5.54%)
What is Takeda Pharmaceutical Company Limited quarterly total liabilities?
The current quarterly total liabilities of TAK is $49.42B
What is the all time high quarterly total liabilities for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly total liabilities is $80.53B
What is Takeda Pharmaceutical Company Limited quarterly total liabilities year-on-year change?
Over the past year, TAK quarterly total liabilities has changed by -$2.98B (-5.68%)